[breadcrumb_custom]

Tag: MNPR Stock

Stock

Monopar Therapeutics Inc (MNPR) Stock: From Low to High in 52 Weeks

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Monopar Therapeutics Inc’s current trading price is -61.88% away from its 52-week high, while its distance from the 52-week low is 374.63%. The stock’s price range for this time frame has been between $0.27 and $3.41. The trading volume of the company’s shares in the Healthcare reached around 60.95 million for the day, which was evidently higher than the average daily volume of 4.36 million over the last three months. In terms of market performance, Monopar Therapeutics Inc had

News

MNPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect?

The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 153.82%. However, over the past six months, we’ve seen a weaker performance of 33.38%. The price of MNPR fallen by 135.61% over the last 30 days. And in the last five days, it has surged by 160.88%. The stock market performance of Monopar Therapeutics Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $3.68 on 02/21/23, while the

Stock Investing

What Drove Monopar Therapeutics (MNPR) Stock Up Nearly 9% After-Hours?

After-hours trading on Monday saw shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) rise 8.78% to $2.23 following the release of encouraging clinical-trial data. What data has MNPR provided? Yesterday, Monopar Therapeutics (MNPR) published encouraging findings with MNPR-202 from its ongoing partnership with the National University of Singapore’s Cancer Science Institute of Singapore (CSI Singapore) (NUS). Next Weekend at the 64th American Society of Hematology (ASH) Plenary Session & Exposition, NUS and Monopar Therapeutics will present a poster with the results (ASH 2022). The poster is accessible on Monopar’s website. A potential DNA Damaging Response (DDR) medication candidate and doxorubicin analog